Physician profile
Ward M Neff
NPI 1588667968
$5,708.10
in general payments reported to CMS, 2019-2025
37 companies · $119 in 2025
The $119 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,819 · 2020: $739 · 2021: $1,055 · 2022: $662 · 2023: $905 · 2024: $409 · 2025: $119.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,433.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,433.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $1,246.72 | 2019-2023 | Evenity, Prolia |
| Astrazeneca Pharmaceuticals LP | $570.94 | 2019-2024 | Airsupra, Farxiga |
| Glaxosmithkline, LLC. | $559.91 | 2019-2024 | Shingrix, Arexvy, Trelegy Ellipta |
| Novo Nordisk INC | $550.82 | 2019-2023 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $512.21 | 2019-2025 | |
| Allergan, INC. | $442.07 | 2019-2020 | |
| Amarin Pharma, INC. | $191.98 | 2019-2020 | |
| Vanda Pharmaceuticals INC. | $186.32 | 2024 | Fanapt |
| Merck Sharp & Dohme LLC | $184.99 | 2019-2023 | Verquvo, Belsomra, Steglatro |
| Novartis Pharmaceuticals Corporation | $172.09 | 2019-2023 | |
| Lilly USA, LLC | $137.35 | 2019-2023 | Mounjaro |
| Pfizer INC. | $126.72 | 2019-2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $76.48 | 2019-2023 | Jardiance |
| Biohaven Pharmaceutical Holding Company LTD. | $63.67 | 2022 | |
| Alkermes, INC. | $61.29 | 2025 | Aristada, Aristada Initio |
Show all 37 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ward Neff listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.